@article{a1af2a202ce34e4ca537f6c6cded0970,
title = "Complications related to a cosmetic eye-whitening procedure",
abstract = "Results: Seventeen eyes of 9 patients underwent cosmetic eye-whitening performed between 2 and 48 months prior to referral to one of the centers. Sixteen of the 17 eyes had persistent conjunctival epithelial defects, with 10 eyes requiring amniotic membrane grafting to facilitate re-epithelialization. Four eyes of 2 patients developed limbal stem cell compromise confirmed with in vivo confocal laser scanning microscopy. One patient developed infectious scleritis and diplopia resulting from Tenon capsule scarring. Another patient developed scleral necrosis, secondary infectious scleritis, and infectious endophthalmitis. This patient subsequently developed noninfectious scleritis that required 3-drug-regimen immunosuppression.Conclusion: Severe adverse effects can occur after extensive cosmetic conjunctival resection followed by topical mitomycin C application. Patients and physicians should be aware of the potential sight-threatening complications associated with this eye-whitening procedure.Purpose: To report sight-threatening complications following extensive bulbar conjunctival resection and postoperative mitomycin C therapy for cosmetic eyewhitening in the United States.Design: Retrospective noncomparative case series.Methods: Multicenter report of 9 patients referred for evaluation and management of complications following bilateral cosmetic eye whitening.",
author = "Vo, {Rosalind C.} and Ksenia Stafeeva and Aldave, {Anthony J.} and Stulting, {R. Doyle} and Quianta Moore and Pflugfelder, {Stephen C.} and Chungfat, {Neil C.} and Holsclaw, {Douglas S.} and Margolis, {Todd P.} and Deng, {Sophie X.}",
note = "Funding Information: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Financial disclosures: T.M.: intellectual property for the patent of a cellphone-based fundus camera and expert witness testimony; S.C.P.: a consultant for Allergan, Glaxo-Smith Kline, and Bausch and Lomb; S.X.D.: filed a patent application on limbal stem cell culture method, a consultant for Bausch and Lomb, and received a lecture fee from Hoya Corp; R.D.S.: expert witness testimony; A.J.A.: a consultant or speaker for Allergan, Bausch and Lomb, Nicox, Santen, and Tear Science, and received travel support from Tissue Banks International. Funding/support: None related to the materials discussed in this manuscript. T.M. receives grant support from the National Eye Institute on Infection on Corneal Neurons with HSV-1 research (R01 EY022697); S.X.D. receives grant support from the California Institute for Regenerative Medicine (TR2-01768) and the National Eye Institute on limbal stem cells (R01 EY021797); A.J.A. receives grant support from the National Eye Institute on cornea endothelial cell research (R01 EY022082), Research to Prevent Blindness. Contributions of authors: design of the study (S.X.D., S.C.P., A.J.A.); collection, management, analysis, and interpretation of data (R.C.V., K.S., N.C., D.H., Q.M., S.X.D., D.H., T.M., R.D.S.); preparation, review, approval of manuscript (R.C.V., K.S., A.J.A., R.D.S., Q.L.M., S.P., N.C., D.H., T.M., S.X.D.); final approval of manuscript (S.X.D.). Publisher Copyright: {\textcopyright} 2014 by Elsevier Inc. All rights reserved.",
year = "2014",
month = nov,
day = "1",
doi = "10.1016/j.ajo.2014.07.032",
language = "English",
volume = "158",
pages = "967--973",
journal = "American journal of ophthalmology",
issn = "0002-9394",
number = "5",
}